- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01194154
A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
April 3, 2017 updated by: Hoffmann-La Roche
A Randomized Controlled, Single-blind, Proof-of-concept-study to Investigate the Protective Effects of Early Treatment With C.E.R.A. in Patients With Chronic Kidney Disease on Renal Disease Progression (PRIMAVERA-Study)
This randomized, single-blind, proof-of-concept study will investigate the protective effects of early treatment with Mircera in participants with chronic kidney disease on renal disease progression.
Participants will be randomly assigned to receive 30 microgram (mcg) Mircera as subcutaneous injection once monthly or matching placebo.
Depending on change of hemoglobin values, the dose of Mircera can be adjusted to 50 mcg or 75 mcg once monthly.
The anticipated time on study treatment is 24 months.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
241
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aachen, Germany, 52057
- Uniklinik RWTH Aachen; Med. Klinik II; Klinik für Nephrologie und klinische Immunologie
-
Augsburg, Germany, 86157
- Dialysepraxis Dr. Stallforth, Dr. Kirschner, Dr. Al-Sarraf und Dr. Pawlik
-
Bad König, Germany, 64732
- KfH Kuratorium für Dialyse und Nierentransplantation e.V. im Kurhaus
-
Berlin, Germany, 10117
- Charité - Klinikum Mitte; Medizinische Klinik Für Nephrologie
-
Berlin, Germany, 12203
- Charité - Campus Benjamin Franklin; Zentrum fuer Innere Medizin, Med. Klinik I
-
Berlin, Germany, 12435
- Gemeinschaftspraxis Dres. Erika Eger, Frank Seibt, Oliver Eike u.w. - Dialysezentrum Treptower Park
-
Bovenden, Germany, 37120
- Dialyse-Institut Bovenden
-
Dresden, Germany, 01307
- Universitätsklinikum "Carl Gustav Carus"; Medizinische Klinik III
-
Düsseldorf, Germany, 40210
- DaVita Clinical Research Deutschland GmbH
-
Essen, Germany, 45122
- Universitätsklinikum Essen Zentrum f.Innere Medizin Abt.Nephrologie
-
Frankfurt, Germany, 60596
- Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik III
-
Heidelberg, Germany, 69120
- Uniklinikum Heidelberg
-
Heilbronn, Germany, 74076
- Dialysepraxis Prof.Dr.med. Michael Rambausek Dres. Stephan Matthias und Gabriele Kunowski - Dialysz.
-
Hilden, Germany, 40724
- Nephrologisches Zentrum Hilden am St. Josefs-Krankenhaus
-
Homburg/Saar, Germany, 66424
- Universitaetsklinikum des Saarlandes; Klinik f. Innere Medizin IV
-
Hoyerswerda, Germany, 02977
- Dres. Jan Nawka und Frank Pistrosch
-
Kaiserslautern, Germany, 67655
- Westpfalz-Klinikum Gmbh; Nephrologie/Transplantationsmedizin
-
Kiel, Germany, 24106
- PHV Patienten-Heimversorgung Dialyse-Station
-
Köln, Germany, 51109
- Kliniken der Stadt Köln gGmbH Krankenhaus Merheim
-
Lübeck, Germany, 23562
- Universitätsklinikum Schleswig-Holstein / Campus Lübeck, Med. Klinik I, Transplantationszentrum
-
Mannheim, Germany, 68309
- Gemienschaftspraxis Dres. Leistikow, Rachti & Sandner
-
Mettmann, Germany, 40822
- Dres. Michael Koch Hannelore Klimke Wolfgang Kulas u.w.
-
Muenchen, Germany, 80336
- Klinikum Innenstadt Medizinische Klinik; Abt.Endokrinologie und Diabetologie
-
München, Germany, 81377
- Klinikum d.Universität München Campus Großhadern
-
München-Bogenhausen, Germany, 81925
- Nierenzentrum Bogenhausen/Perlach; Praxis für Nierenheilkunde
-
Münster, Germany, 48149
- Universitätsklinikum Münster Innere Medizin D
-
Neckarsulm, Germany, 74172
- Dres. Georg Fuchs und Nexhat Miftari
-
Neunkirchen/Saar, Germany, 66538
- Nephrologische Praxis Neunkirchen - Dr.med. Klemens Dorr und Artem Goldmann
-
Saarlouis, Germany, 66740
- Dialysezentrum Saarlouis
-
Ulm, Germany, 89077
- Gemeinschaftspraxis Rosemarie Krämer und Lars Rothermund
-
Velbert, Germany, 42549
- Nephrologisches Zentrum
-
Villingen-Schwenningen, Germany, 78052
- Nephrologisches Zentrum Dialyse-Institut
-
Wiesbaden, Germany, 65191
- KfH Kuratiorium für Dialyse und Nierentransplantation e.V.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- For diabetic participants: Type 2 diabetes mellitus with glycated hemoglobin (HbA1c) greater than (>) 7% or anti-diabetic treatment
- For renal allograft recipients: Status at least 6 months post transplantation
- Chronic kidney disease stage III
- Urinary albumin-to-creatinine ratio less than (<) 3000 milligram (mg)/gram (g) or total protein <3000 mg/ 24 hour urine sample where applicable
Exclusion Criteria:
- Hemoglobin-level < 11 or > 14 g/deciliter (dL)
- Average systolic blood pressure (SBP) > 140 millimeter of mercury (mm Hg) or average diastolic blood pressure (DBP) > 90 mm Hg
- Initiation of angiotensin converting enzyme inhibitor, angiotensin 2 receptor blocker or aliskiren treatment less than 3 months before enrolment
- Present and known iron deficiency
- HbA1c >9%
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
|
Experimental: Mircera
|
Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Yearly Reduction Rate of Estimated Glomerular Filtration Rate (eGFR) Calculated by Modification of Diet in Renal Disease With 4 Variables (MDRD-4)
Time Frame: 24 months
|
The yearly reduction in eGFR was calculated using the MDRD-4 formula.
This formula is based on age, sex, and serum creatinine and eGFR values are calculated as follows: GFR in milliliter per minute (mL/min) per 1.73 meter square (m^2) = 175 x Serum Cr^-1.154
x age^-0.203
x 0.742 (if female).
The yearly reduction rate (mL/min/1.73m^2
/ Year) is defined as -365.25 multiplied by Beta, where Beta is the slope parameter derived for each participants separately by simple linear regression of the change from baseline in participant's eGFR measurements (from Baseline to Visit 24) on the actual day of measurement.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Yearly Reduction Rate of Estimated Glomerular Filtration Rate (eGFR) Calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
Time Frame: 24 months
|
The eGFR value calculated using the CKD-EPI equation.
The formula used is based on age, sex, ethnicity, and serum creatinine and eGFR values are calculated as follows: GFR in mL/min per 1.73 m^2 = 141 x min (SerumCr/k; 1)^a x max(SerumCr/k; 1)^(-1.209)
x 0.993^age x F x B, where k=0.7 for female (else=0.9);
a=-0.329 for female (else=-0.411),
F=1.018 for female (else=1), B=1.159 for black (else=1), min/max=minimum/maximum of listed values.
The Yearly Reduction Rate (mL/min/1.73m^2
/ Year) is defined as -365.25 x Beta, where Beta is the slope parameter derived for each participant separately by simple linear regression of the change from baseline in participant's eGFR measurements (from Baseline to Visit 24) on the actual day of measurement.
|
24 months
|
Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at Month 24
Time Frame: Baseline, Month 24
|
Creatinine clearance was calculated according to the Cockcroft and Gault Formula.
It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys.
Normal adult creatinine clearance is greater than or equal to (>=) 90 mL/min.
Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function.
|
Baseline, Month 24
|
Change From Baseline in Serum Creatinine Concentration at Month 24
Time Frame: Baseline, Month 24
|
Serum creatinine is an indicator of kidney function.
Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue.
It is removed from the blood by the kidneys and excreted in urine.
Normal adult blood levels of creatinine=45 to 90 micromoles per liter (mcmol/L) for females, 60 to 110 mcmol/L for males, however normal values are age-dependent.
|
Baseline, Month 24
|
Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Month 24
Time Frame: Baseline, Month 24
|
UACR is defined as the ratio: milligram of albumin per gram of creatinine.
The presence of albumin in the urine (macroalbuminuria) is a marker of kidney disease.
Albumin and creatinine concentrations were obtained from spot urine samples.
|
Baseline, Month 24
|
Change From Baseline in Serum Cystatin C Concentration at Month 24
Time Frame: Baseline, Month 24
|
Cystatin C is a protein which is mainly used as a biomarker of kidney function.
If kidney function and GFR decline, the blood levels of cystatin C rise.
|
Baseline, Month 24
|
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: 24 months
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; and congenital anomaly.
Percentage of participants with AEs included participants affected with both SAEs and non-SAEs.
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 30, 2010
Primary Completion (Actual)
March 31, 2015
Study Completion (Actual)
March 31, 2015
Study Registration Dates
First Submitted
August 25, 2010
First Submitted That Met QC Criteria
September 1, 2010
First Posted (Estimate)
September 2, 2010
Study Record Updates
Last Update Posted (Actual)
May 10, 2017
Last Update Submitted That Met QC Criteria
April 3, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ML22916
- 2009-015114-22
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Disease, Chronic
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on Methoxy polyethylene glycol-epoetin beta
-
Chugai PharmaceuticalCompleted
-
Hoffmann-La RocheCompletedRenal Insufficiency, Chronic | AnemiaUnited States, Spain, France, Hungary, Italy, Lithuania, Poland
-
Hoffmann-La RocheCompletedAnemiaUnited States, Canada, United Kingdom, Mexico, Poland
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompleted
-
Chugai PharmaceuticalCompleted
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedAnemiaItaly, Spain, United States, Germany
-
Hoffmann-La RocheCompleted